Kura Oncology vs Tango Therapeutics
KURA and TNGX side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How KURA and TNGX compare
Tango Therapeutics is the larger company, worth 5.9 times as much as Kura Oncology ($3.8B against $654M).
Tango Therapeutics keeps more of each dollar of sales as profit, with a net margin of −230% compared with −369% at Kura Oncology.
Tango Therapeutics scores higher on the StockData Score (10 against 1 for Kura Oncology), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | KURA | TNGX |
|---|---|---|
| Size and price | ||
| Market cap | $654M | $3.8B |
| Share price | $7.35 | $22.71 |
| Change, 1 year | −33.7% | 184% |
| Change, 5 years | −47.5% | 119% |
| Beta (5Y) | 1.27 | 1.18 |
| Employees | 260 | 137 |
| StockData Score | ||
| Total score | 1 | 10 (better) |
| Valuation score | 0 | 0 |
| Growth score | 0 | 2 (better) |
| Performance score | 0 | 2 (better) |
| Health score | 1 | 6 (better) |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 8.2× (better) | 71.2× |
| P/B | 36.4× | 3.7× (better) |
| FCF yield | −13.6% | −3.8% (better) |
| Fair value | – | $9.65 |
| Margin of safety | – | −135% |
| Growth | ||
| Revenue growth (TTM) | – | 121% |
| Revenue growth, 5Y average | – | 52.1% |
| Profitability | ||
| Operating margin | −394% | −253% (better) |
| Net margin | −369% | −230% (better) |
| FCF margin | −112% (better) | −268% |
| Return on equity | −225% | −21.3% (better) |
| Financial health | ||
| Debt / equity | 0.55 (better) | 0.00 |
| Interest coverage | −227.1× | – |
| Current ratio | 3.60 | 50.82 (better) |
| Altman Z-score | −3.57 | 46.40 (better) |
| Piotroski F-score | 1 | 4 (better) |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 98.0% | 127% |
| Held by insiders | 2.6% | 11.7% |
| Insider net buying, 12 months | $1.3M (better) | −$8.1M |
| Short interest, % of float | 14.6% | 32.4% |
Go deeper
- KURA stock overview
- KURA income statement
- KURA valuation and score
- TNGX stock overview
- TNGX income statement
- TNGX valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.